Cilengitide (Linear) RGDFV-acid

Description

Cyclic arginine-glycine-aspartic acid motif containing peptide; selectively inhibits integrin αv subunit.

See full description

Catalogue number crb1001070
Sequence (one letter code) RGDFV-acid
Sequence (three letter code) H-Arg-Gly-Asp-Phe-Val-OH
Purity >95%
Storage -20°C
Molecular Weight 592.3
References

Cheng et al (2014) Cilengitide Inhibits Attachment and Invasion of Malignant Pleural Mesothelioma Cells through Antagonism of Integrins αvβ3 and αvβ5. PLoS ONE 9(3) e90374 PMID: 24595274

Cilengitide is a cyclic arginine-glycine-aspartic acid (RGD) motif containing peptide that selectively inhibits the integrin αv subunit. Integrins are cell adhesion molecules which mediate cell-cell and cell-matrix interactions and creating a scaffold for tissue organisation. Integrins also act to regulate cell, attachment, proliferation, differentiation, apoptosis and motility.
Integrin αv can form heterodimers with integrin subunits subunits β1, β3, β5, β6, or β8. Cilengitide is a highly specific antagonist of αvβ3 and αvβ5 integrins. It also and shows anti-angiogenic effects and inhibits growth and promotes apoptosis of tumour cells that express integrins, such as glioblastoma.
Cilengitide has gone on to phase II trials for cancers such as glioblastoma, melanoma, prostate, breast, lung and head and neck cancers.

Cilengitide (Linear)

Cat No. Pack Size Price Qty

crb1001070h

0.5mg

$112.50

crb1001070j

1mg

$150.00